|
1
|
Moore DD and Luu HH: Osteosarcoma. Cancer
Treat Res. 162:65–92. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lamoureux F, Trichet V, Chipoy C,
Blanchard F, Gouin F and Redini F: Recent advances in the
management of osteosarcoma and forthcoming therapeutic strategies.
Expert Rev Anticancer Ther. 7:169–181. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Luetke A, Meyers PA, Lewis I and Juergens
H: Osteosarcoma treatment-where do we stand? A state of the art
review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sakamoto A and Iwamoto Y: Current status
and perspectives regarding the treatment of osteo-sarcoma:
Chemotherapy. Rev Recent Clin Trials. 3:228–231. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chou AJ and Gorlick R: Chemotherapy
resistance in osteosarcoma: Current challenges and future
directions. Expert Rev Anticancer Ther. 6:1075–1085. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Katoh M and Katoh M: Human FOX gene family
(Review). Int J Oncol. 25:1495–1500. 2004.PubMed/NCBI
|
|
7
|
Alvarez B, Martinez-A C, Burgering BM and
Carrera AC: Forkhead transcription factors contribute to execution
of the mitotic programme in mammals. Nature. 413:744–747. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Furukawa-Hibi Y, Kobayashi Y, Chen C and
Motoyama N: FOXO transcription factors in cell-cycle regulation and
the response to oxidative stress. Antioxid Redox Signal. 7:752–760.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fu Z and Tindall DJ: FOXOs, cancer and
regulation of apoptosis. Oncogene. 27:2312–2319. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo
P, Hu LS, Anderson MJ, Arden KC, Blenis J and Greenberg ME: Akt
promotes cell survival by phosphorylating and inhibiting a forkhead
transcription factor. Cell. 96:857–868. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Park SH, Chung YM, Ma J, Yang Q, Berek JS
and Hu MC: Pharmacological activation of FOXO3 suppresses
triple-negative breast cancer in vitro and in vivo. Oncotarget.
7:42110–42125. 2016.PubMed/NCBI
|
|
12
|
Park SH, Lee JH, Berek JS and Hu MC:
Auranofin displays anticancer activity against ovarian cancer cells
through FOXO3 activation independent of p53. Int J Oncol.
45:1691–1698. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fei M, Zhao Y, Wang Y, Lu M, Cheng C,
Huang X, Zhang D, Lu J, He S and Shen A: Low expression of Foxo3a
is associated with poor prognosis in ovarian cancer patients.
Cancer Invest. 27:52–59. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lu M, Zhao Y, Xu F, Wang Y, Xiang J and
Chen D: The expression and prognosis of FOXO3a and Skp2 in human
ovarian cancer. Med Oncol. 29:3409–3415. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jancic J, Nikolic B, Ivancevic N, Djuric
V, Zaletel I, Stevanovic D, Peric S, van den Anker JN and Samardzic
J: Multiple sclerosis in pediatrics: Current concepts and treatment
options. Neurol Ther. 5:131–143. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Atwal M, Lishman EL, Austin CA and Cowell
IG: Myeloperoxidase enhances etoposide and mitoxantrone-mediated
DNA damage: A target for myeloprotection in cancer chemotherapy.
Mol Pharmacol. 91:49–57. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Casadei B, Pellegrini C, Pulsoni A,
Annechini G, De Renzo A, Stefoni V, Broccoli A, Gandolfi L, Quirini
F, Tonialini L, et al: 90-yttrium-ibritumomab tiuxetan
consolidation of fludarabine, mitoxantrone, rituximab in
intermediate/high-risk follicular lymphoma: Updated long-term
results after a median follow-up of 7 years. Cancer Med.
5:1093–1097. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nussbaum N, George DJ, Abernethy AP, Dolan
CM, Oestreicher N, Flanders S and Dorff TB: Patient experience in
the treatment of metastatic castration-resistant prostate cancer:
State of the science. Prostate Cancer Prostatic Dis. 19:111–121.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hasinoff BB, Wu X, Patel D, Kanagasabai R,
Karmahapatra S and Yalowich JC: Mechanisms of action and reduced
cardiotoxicity of pixantrone; a topoisomerase II targeting agent
with cellular selectivity for the topoisomerase IIα isoform. J
Pharmacol Exp Ther. 356:397–409. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ferrer A, Marce S, Bellosillo B, Marcé S,
Bellosillo B, Villamor N, Bosch F, López-Guillermo A, Espinet B,
Solé F, Montserrat E, Campo E and Colomer D: Activation of
mitochondrial apoptotic pathway in mantle cell lymphoma: High
sensitivity to mitoxantrone in cases with functional DNA-damage
response genes. Oncogene. 23:8941–8949. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chong CR and Sullivan DJ Jr: New uses for
old drugs. Nature. 448:645–646. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rena G, Woods YL, Prescott AR, Peggie M,
Unterman TG, Williams MR and Cohen P: Two novel phosphorylation
sites on FKHR that are critical for its nuclear exclusion. EMBO J.
21:2263–2271. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bae JS, Lee J, Park Y, Park K, Kim JR, Cho
DH, Jang KY and Park SH: Attenuation of MUC4 potentiates the
anticancer activity of auranofin via regulation of the
Her2/Akt/FOXO3 pathway in ovarian cancer cells. Oncol Rep.
38:2417–2425. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
ESMO/European Sarcoma Network Working
Group: Bone sarcomas: ESMO clinical practice guidelines for
diagnosis, treatment and follow-up. Ann Oncol. 25:iii113–iii123.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zambo I and Veselý K: WHO classification
of tumours of soft tissue and bone 2013: The main changes compared
to the 3rd edition. Cesk Patol. 50:64–70. 2014.(In Czech).
PubMed/NCBI
|
|
26
|
Schajowicz F, McGuire MH, Araujo Santini
E, Muscolo DL and Gitelis S: Osteosarcomas arising on the surfaces
of long bones. J Bone Joint Surg Am. 70:555–564. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Grimer RJ, Bielack S, Flege S, Cannon SR,
Foleras G, Andreeff I, Sokolov T, Taminiau A, Dominkus M,
San-Julian M, et al: Periosteal osteosarcoma-a European review of
outcome. Eur J Cancer. 41:2806–2811. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cesari M, Alberghini M, Vanel D, Palmerini
E, Staals EL, Longhi A, Abate M, Ferrari C, Balladelli A and
Ferrari S: Periosteal osteosarcoma: A single-institution
experience. Cancer. 117:1731–1735. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bernthal NM, Federman N, Eilber FR, Nelson
SD, Eckardt JJ, Eilber FC and Tap WD: Long-term results (>25
years) of a randomized, prospective clinical trial evaluating
chemotherapy in patients with high-grade, operable osteosarcoma.
Cancer. 118:5888–5893. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bielack SS, Smeland S, Whelan JS, Marina
N, Jovic G, Hook JM, Krailo MD, Gebhardt M, Pápai Z, Meyer J, et
al: Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance
pegylated interferon Alfa-2b versus MAP alone in patients with
resectable high-grade osteosarcoma and good histologic response to
preoperative MAP: First results of the EURAMOS-1 good response
randomized controlled trial. J Clin Oncol. 33:2279–2287. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Benjamin RS, Wagner MJ, Livingston JA,
Ravi V and Patel SR: Chemotherapy for bone sarcomas in adults: The
MD anderson experience. Am Soc Clin Oncol Educ Book. e656–e660.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Su W, Lai Z, Wu F, Lin Y, Mo Y, Yang Z and
Wu J: Clinical efficacy of preoperative chemotherapy with or
without ifosfamide in patients with osteosarcoma of the extremity:
Meta-analysis of randomized controlled trials. Med Oncol.
32:4812015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Navid F, Willert JR, McCarville MB, Furman
W, Watkins A, Roberts W and Daw NC: Combination of gemcitabine and
docetaxel in the treatment of children and young adults with
refractory bone sarcoma. Cancer. 113:419–425. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rodriguez-Galindo C, Daw NC, Kaste SC,
Meyer WH, Dome JS, Pappo AS, Rao BN and Pratt CB: Treatment of
refractory osteosarcoma with fractionated cyclophosphamide and
etoposide. J Pediatr Hematol Oncol. 24:250–255. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Saylors RL 3rd, Stine KC, Sullivan J,
Kepner JL, Wall DA, Bernstein ML, Harris MB, Hayashi R and Vietti
TJ: Pediatric Oncology Group: Cyclophosphamide plus topotecan in
children with recurrent or refractory solid tumors: A pediatric
oncology group phase II study. J Clin Oncol. 19:3463–3469. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Merimsky O, Meller I, Kollender Y, Issakov
J, Flusser G and Inbar M: Gemcitabine in bone sarcoma resistant to
doxorubicin-based chemotherapy. Sarcoma. 4:7–10. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Goorin AM, Harris MB, Bernstein M,
Ferguson W, Devidas M, Siegal GP, Gebhardt MC, Schwartz CL, Link M
and Grier HE: Phase II/III trial of etoposide and high-dose
ifosfamide in newly diagnosed metastatic osteosarcoma: A pediatric
oncology group trial. J Clin Oncol. 20:426–433. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Van Winkle P, Angiolillo A, Krailo M,
Cheung YK, Anderson B, Davenport V, Reaman G and Cairo MS:
Ifosfamide, carboplatin, and etoposide (ICE) reinduction
chemotherapy in a large cohort of children and adolescents with
recurrent/refractory sarcoma: The children's cancer group (CCG)
experience. Pediatr Blood Cancer. 44:338–347. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Michelagnoli MP, Lewis IJ, Gattamaneni HR,
Bailey CC and Lashford LS: Ifosfamide/etoposide alternating with
high-dose methotrexate: Evaluation of a chemotherapy regimen for
poor-risk osteosarcoma. Br J Cancer. 79:1174–1178. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Anderson PM, Wiseman GA, Dispenzieri A,
Arndt CA, Hartmann LC, Smithson WA, Mullan BP and Bruland OS:
High-dose samarium-153 ethylene diamine tetramethylene phosphonate:
Low toxicity of skeletal irradiation in patients with osteosarcoma
and bone metastases. J Clin Oncol. 20:189–196. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hattinger CM, Vella S, Tavanti E, Fanelli
M, Picci P and Serra M: Pharmacogenomics of second-line drugs used
for treatment of unresponsive or relapsed osteosarcoma patients.
Pharmacogenomics. 17:2097–2114. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liu T, Li Z, Zhang Q, De Amorim Bernstein
K, Lozano-Calderon S, Choy E, Hornicek FJ and Duan Z: Targeting
ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the
CRISPR-Cas9 system to reverse drug resistance. Oncotarget.
7:83502–83513. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Buondonno I, Gazzano E, Jean SR, Audrito
V, Kopecka J, Fanelli M, Salaroglio IC, Costamagna C, Roato I,
Mungo E, et al: Mitochondria-targeted doxorubicin: A new
therapeutic strategy against doxorubicin-resistant osteosarcoma.
Mol Cancer Ther. 15:2640–2652. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chen Z, Guo J, Zhang K and Guo Y: TP53
mutations and survival in osteosarcoma patients: A meta-analysis of
published data. Dis Markers. 2016:46395752016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ru JY, Cong Y, Kang WB, Yu L, Guo T and
Zhao JN: Polymorphisms in TP53 are associated with risk and
survival of osteosarcoma in a Chinese population. Int J Clin Exp
Pathol. 8:3198–3203. 2015.PubMed/NCBI
|
|
46
|
Yao D, Cai GH, Chen J, Ling R, Wu SX and
Li YP: Prognostic value of p53 alterations in human osteosarcoma: A
meta analysis. Int J Clin Exp Pathol. 7:6725–6733. 2014.PubMed/NCBI
|
|
47
|
Pakos EE, Kyzas PA and Ioannidis JP:
Prognostic significance of TP53 tumor suppressor gene expression
and mutations in human osteosarcoma: A meta-analysis. Clin Cancer
Res. 10:6208–6214. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ozaki T, Wu D, Sugimoto H, Nagase H and
Nakagawara A: Runt-related transcription factor 2 (RUNX2) inhibits
p53-dependent apoptosis through the collaboration with HDAC6 in
response to DNA damage. Cell Death Dis. 4:e6102013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Tarrado-Castellarnau M, Cortes R, Zanuy M,
Tarragó-Celada J, Polat IH, Hill R, Fan TW, Link W and Cascante M:
Methylseleninic acid promotes antitumour effects via nuclear FOXO3a
translocation through Akt inhibition. Pharmacol Res. 102:218–234.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Guzman-Perez V, Bumke-Vogt C, Schreiner M,
Mewis I, Borchert A and Pfeiffer AF: Benzylglucosinolate Derived
Isothiocyanate from Tropaeolum majus Reduces Gluconeogenic Gene and
Protein Expression in Human Cells. PLoS One. 11:e01623972016.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Jin S, Pang RP, Shen JN, Huang G, Wang J
and Zhou JG: Grifolin induces apoptosis via inhibition of PI3K/AKT
signalling pathway in human osteosarcoma cells. Apoptosis.
12:1317–1326. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Pei H, Jin Z, Chen S, Sun X, Yu J and Guo
W: MiR-135b promotes proliferation and invasion of osteosarcoma
cells via targeting FOXO1. Mol Cell Biochem. 400:245–252. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Toker A and Marmiroli S: Signaling
specificity in the Akt pathway in biology and disease. Adv Biol
Regul. 55:28–38. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Yuan CL, Lin SW and Cheng MH: Inhibition
of Molecular Signaling in Huh-7 Cells by AM3: A Novel
Chemotherapeutic Agent for Hepatocellular Carcinoma. Med Chem.
49–56. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Hu T, Cao H, Yang C, Zhang L, Jiang X, Gao
X, Yang F, He G, Song X, Tong A, et al: LHD-modified
mechanism-based liposome coencapsulation of Mitoxantrone and
Prednisolone using novel lipid bilayer fusion for tissue-specific
colocalization and synergistic antitumor effects. ACS App Mater
Interfaces. 8:6586–6601. 2016. View Article : Google Scholar
|
|
56
|
Matsuda T, Kato T, Kiyotani K, Tarhan YE,
Saloura V, Chung S, Ueda K, Nakamura Y and Park JH: p53-independent
p21 induction by MELK inhibition. Oncotarget. 8:57938–57947. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Liu H, Yin J, Wang C, Gu Y, Deng M and He
Z: FOXO3a mediates the cytotoxic effects of cisplatin in lung
cancer cells. Anticancer Drugs. 25:898–907. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Zhang YX, Liu XM, Wang J, Li J, Liu Y,
Zhang H, Yu XW and Wei N: Inhibition of AKT/FoxO3a signaling
induced PUMA expression in response to p53-independent cytotoxic
effects of H1: A derivative of tetrandrine. Cancer Biol Ther.
16:965–975. 2015. View Article : Google Scholar : PubMed/NCBI
|
